Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knight grosses $Cdn180mm in special warrant sale, the second this month

Executive Summary

Infectious disease-focused Knight Therapeutics Inc. grossed $Cdn180mm ($161mm) through a private placement of 34.3mm special warrants at $Cdn5.25. At no cost, each special warrant can be exercised for one Knight common share either on a date no later than the fifth business day after the final prospectus is issued, or four months and one day after the offering closes, whichever is earlier. An affiliate owned by Knight’s CEO agreed to purchase 7.62mm special warrants, worth about $Cdn40mm. Earlier this month, Knight grossed $Cdn75mm in a separate special warrant financing.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register